Screening for prostate cancer

Annals of Internal Medicine

Volumn 126, Issue 6, 1997, Pages 480-484

  Coley, C M ^a   Barry, M J ^a   Mulley, A G ^a   Thibault, G E ^a   Feussner, J R ^a   Audet A , M J ^a   Friesinger C , Jr ^a   Kent, D L ^a   Marton, K I ^a   Palda, V A ^a   Whyte, J J ^a   Winters, P I ^a  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN DETECTION; ARTICLE; CANCER SCREENING; DIAGNOSTIC APPROACH ROUTE; HUMAN; NEEDLE BIOPSY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

COUNSELING; HUMANS; MALE; MASS SCREENING; PHYSICAL EXAMINATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; RISK FACTORS;

EID: 0031055722     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. Cancer. 1995;45:8-30.
2. Thompson IM, Zeidman EJ. Current urological practice: routine urological examination and early detection of carcinoma of the prostate. J Urol. 1992;148:326-30.
3. Voss JD. Prostate cancer, screening, and prostate-specific antigen: promise or peril? J Gen Intern Med. 1994;9468-74.
4. Demers RY, Swanson GM, Weiss LK, Kau TY. Increasing incidence of cancer of the prostate: the experience of black and white men in the Detroit metropolitan area. Arch Intern Med. 1994;154:1211-6.
5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-52.
6. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-6.
7. Screening for prostate cancer: commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination. The U.S. Preventive Services Task Force. Am J Prev Med. 1994;10:187-93.
8. Periodic health examination, 1991 update. 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1991;145:413-28.
9. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994;152(5 Pt 2):1905-9.
10. Wilt TJ, Brawer MK. The Prostate Cancer Versus Observational Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostatic cancer. J Urol. 1994;152:1910-4.
11. Prorok P. The National Cancer Institute Multi-Screening Trial. Can J Oncol. 1994;4(Suppl 1):98-9.
12. Schroder FH. The European Screening Study for Prostate Cancer. Can J Oncol. 1994;4(Suppl 1):102-5.
13. Aronowitz R. To screen or not to screen: what is the question? [Editorial] J Gen Intern Med. 199510:295-7.
14. Brett AS. The mammography and prostate-specific antigen controversies. Implications for patient-physician encounters and public policy. J Gen Intern Med. 1995;10:266-70.
15. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338:469-71.
16. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-9.
17. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-90.
18. Gerber GS, Thompson IM, Thisted R, Chodak GW. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA. 1993;269:61-4.
19. Friedman GD, Hiatt RA, Quesenberry CP, Selby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet. 1991;337:1526-9.
20. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42:365-74.
21. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol. 1989;141:1136-8.
22. Gustafsson O, Norming U, Almgard LE, Frederiksson A, Gustavsson G, Harvig B, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol. 1992;148:1827-31.
23. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination for early detection of prostate cancer. Urology. 1995;45:70-4.
24. Varenhorst E, Berglund K, Lofman O, Pedersen K. Inter-observer variation in assessment of the prostate by digital rectal examination. Br J Urol. 1993;72:173-6.
25. Pederson KV, Carlsson P, Varenhorst E, Lofman O, Berglund K, Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ. 1990;300:1041-4.
26. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM. Influence of patient age on the serum PSA concentration: an important clinical observation. Urol Clin North Am. 1993;20:671-80.
27. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol. 1995;153:1160-3.
28. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without evidence of prostatic carcinoma. J Urol. 1993;150:1837-9.
29. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babian R, et al. Characteristics of prostate cancer detected in the American Cancer Society National Prostate Cancer Detection Project. J Urol. 1994;152:1737-40.
30. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152(6 Pt 1):2037-42.
31. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol. 1992;147(3 Pt 2):810-4.
32. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA. 1992;267:2227-8.
33. Oesterling JE, Rice DC, Glenski WJ, Bergstrath EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993;42:276-82.
34. Klomp ML, Hendrikx AJ, Keyzer JJ. The effect of transrectal ultrasonography (TRUS) including digital rectal examination (DRE) of the prostate on the level of prostate specific antigen (PSA). Br J Urol. 1994;73:71-4.
35. Gann PH, Hennekens CH, Meir JS. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289-94.
36. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147:841-5.
37. Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community based study. South Med J. 1994;87:720-3.
38. Muschenheim F, Omarbasha B, Kardijan PM, Mondou EN. Screening for carcinoma of the prostate specific antigen. Ann Clin Lab Sci. 1991;21:371-80.
39. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-61.
40. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804-18.
41. Webb JA, Shanmuganathan K, McLean A. Complications of ultrasound-guided transperineal prostate biopsy, a prospective study. Br J Urol. 1993;72:775-7.
42. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993;2:487-93.
43. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare experience: 1988-1990 (updated June 1993). Urology. 1993;42:622-9.
44. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993;269:2650-8.
45. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? III. Management strategies and outcomes. Urology. 1995;46:277-89.
46. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337-47.
47. Spitz MR, Currier RD, Fueger JJ, Babian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol. 1991;146:1305-7.
48. Ries LA, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Bethesda, MD: National Cancer Institute; 1994. NIH publication no. 94-2789.
49. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst. 1991;83:551-7.
50. Marshalt KG. Screening for prostate cancer. How can patients give informed consent? Can Fam Physician. 1993;39:2385-90.
51. Hahn DL, Roberts RG. PSA screening for asymptomatic prostate cancer: truth in advertising [Editorial]. J Fam Pract. 1993;37:432-6.
52. Flood AB, Wennberg JE, Nease RF, Fowler FJ Jr, Ding J, Hynes LM. The importance of patient preferences in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. J Gen Intern Med. 1996;11:342-9.